Adial Pharmaceuticals, Inc. financial data

Symbol
ADIL on Nasdaq
Location
1180 Seminole Trail, Suite 495, Charlottesville, VA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 424 %
Debt-to-equity 24.6 %
Return On Equity -191 % +34.3%
Return On Assets -154 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.8M shares +241%
Common Stock, Shares, Outstanding 21.5M shares +402%
Entity Public Float 4.83M USD -10.3%
Common Stock, Value, Issued 21.5K USD +402%
Weighted Average Number of Shares Outstanding, Basic 26.5M shares +14.3%
Weighted Average Number of Shares Outstanding, Diluted 10.6M shares +154%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.24M USD +99.2%
General and Administrative Expense 5.06M USD +1.32%
Operating Income (Loss) -8.3M USD -25.4%
Nonoperating Income (Expense) -148K USD +97%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.19M USD -62.6%
Net Income (Loss) Attributable to Parent -8.45M USD +31%
Earnings Per Share, Basic 0 USD/shares +93.6%
Earnings Per Share, Diluted 0 USD/shares +93.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.91M USD +79.9%
Assets, Current 6.08M USD +59%
Property, Plant and Equipment, Net 48.5K USD -13.7%
Operating Lease, Right-of-Use Asset 180K USD -22.8%
Intangible Assets, Net (Excluding Goodwill) 3.07K USD -15.6%
Goodwill 249K USD 0%
Assets 6.8M USD +37.4%
Accounts Payable, Current 671K USD +112%
Accrued Liabilities, Current 540K USD +61.1%
Liabilities, Current 1.21M USD +80.2%
Deferred Income Tax Liabilities, Net 22.9K USD -2.15%
Operating Lease, Liability, Noncurrent 135K USD -30.3%
Liabilities 1.21M USD +80.2%
Retained Earnings (Accumulated Deficit) -86.2M USD -10.9%
Stockholders' Equity Attributable to Parent 5.59M USD +30.7%
Liabilities and Equity 6.8M USD +37.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.59M USD +2.51%
Net Cash Provided by (Used in) Financing Activities 50.6K USD -98.7%
Net Cash Provided by (Used in) Investing Activities 150K USD
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 21.5M shares +402%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.91M USD +79.9%
Deferred Tax Assets, Valuation Allowance 15.6M USD +15%
Deferred Tax Assets, Gross 38.3K USD +8669%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 14M USD +13.6%
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 18K USD +2.34%
Additional Paid in Capital 91.8M USD +11.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 141 USD 0%
Deferred Tax Assets, Net of Valuation Allowance 437 USD +13.8%
Share-based Payment Arrangement, Expense 729K USD -25.4%
Operating Leases, Future Minimum Payments Due 214K USD -24.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%